PODD Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 12.96% compared to Insulet Corp.'s net margin of 12.68%. Insulet Corp.'s return on equity of 17.89% beat Boston Scientific Corp.'s return on equity of 12.55%.

Insulet Corp. has a consensus price target of $354.40, signalling upside risk potential of 46.54%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 41.84%. Given that Insulet Corp. has higher upside potential than Boston Scientific Corp., analysts believe Insulet Corp. is more attractive than Boston Scientific Corp..

Insulet Corp. has a beta of 1.422, which suggesting that the stock is 42.204% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.155%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $783.8M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Insulet Corp.'s net income of $101.6M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Insulet Corp.'s price-to-earnings ratio is 69.08x while Boston Scientific Corp.'s PE ratio is 38.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 6.39x versus 5.50x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 12.96% compared to Insulet Corp.'s net margin of 27.89%. Insulet Corp.'s return on equity of 17.89% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Insulet Corp. has a consensus price target of $354.40, signalling upside risk potential of 46.54%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $609.82 which suggests that it could grow by 22.6%. Given that Insulet Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Insulet Corp. is more attractive than Intuitive Surgical, Inc..

Insulet Corp. has a beta of 1.422, which suggesting that the stock is 42.204% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.814%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $783.8M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Insulet Corp.'s net income of $101.6M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Insulet Corp.'s price-to-earnings ratio is 69.08x while Intuitive Surgical, Inc.'s PE ratio is 63.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 6.39x versus 17.93x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 12.96% compared to Insulet Corp.'s net margin of 11.84%. Insulet Corp.'s return on equity of 17.89% beat Stryker Corp.'s return on equity of 15.17%.

Insulet Corp. has a consensus price target of $354.40, signalling upside risk potential of 46.54%. On the other hand Stryker Corp. has an analysts' consensus of $424.90 which suggests that it could grow by 10.48%. Given that Insulet Corp. has higher upside potential than Stryker Corp., analysts believe Insulet Corp. is more attractive than Stryker Corp..

Insulet Corp. has a beta of 1.422, which suggesting that the stock is 42.204% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.663%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.88% to investors and pays a quarterly dividend of $0.88 per share. Insulet Corp. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Insulet Corp. quarterly revenues are $783.8M, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Insulet Corp.'s net income of $101.6M is lower than Stryker Corp.'s net income of $849M. Notably, Insulet Corp.'s price-to-earnings ratio is 69.08x while Stryker Corp.'s PE ratio is 45.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 6.39x versus 5.92x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of 12.96% compared to Insulet Corp.'s net margin of -0.2%. Insulet Corp.'s return on equity of 17.89% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.

Insulet Corp. has a consensus price target of $354.40, signalling upside risk potential of 46.54%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $29.59 which suggests that it could grow by 24.65%. Given that Insulet Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Insulet Corp. is more attractive than Tandem Diabetes Care, Inc..

Insulet Corp. has a beta of 1.422, which suggesting that the stock is 42.204% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.626, suggesting its more volatile than the S&P 500 by 62.563%.

Insulet Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

Insulet Corp. quarterly revenues are $783.8M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. Insulet Corp.'s net income of $101.6M is higher than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, Insulet Corp.'s price-to-earnings ratio is 69.08x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet Corp. is 6.39x versus 1.57x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.